Aberdeen Group
WVE icon

Aberdeen Group’s Wave Life Sciences WVE Stock Holding History

Aberdeen Group’s Portfolio WVE Stock Details WVE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$5.09M Buy
876,458
+326,458
+59% +$2.16M 0.01% 690
2026
Q1 		$3.99M Buy
+550,000
New +$7.17M 0.01% 713

Other funds holding WVE

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
GP
GSK plc London $602M AUM
MC
Maverick Capital Dallas, Texas $11.3B AUM 76.6% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
6CM
683 Capital Management New York $2.04B AUM 94.26% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
RAM
Readystate Asset Management Chicago, Illinois $2.93B AUM 18.57% 1-Year Est. Return

Aberdeen Group's WVE Position: Q2 2026 in Review

Aberdeen Group increased its Wave Life Sciences (WVE) stake by 59% in Q2 2026, buying an estimated $2.16M and bringing the position to 876,458 shares worth $5.09M. The position accounts for 0.01% of the portfolio, ranked #690.

Aberdeen Group first reported a position in WVE in Q1 2026 and has held it in 2 quarters since. 239 funds tracked by Wall St. Rank hold WVE as of Q2 2026.

  • Aberdeen Group held 876,458 shares of Wave Life Sciences worth $5.09M as of Q2 2026.
  • Aberdeen Group bought 326,458 Wave Life Sciences shares in Q2 2026, an estimated $2.16M.
  • Wave Life Sciences made up 0.01% of Aberdeen Group's portfolio in Q2 2026, its #690 holding.
  • Aberdeen Group first reported a position in Wave Life Sciences in Q1 2026 and has held it in 2 quarters since.
  • 239 funds tracked by Wall St. Rank held Wave Life Sciences as of Q2 2026.

Based on Aberdeen Group's 13F filing for Q2 2026, filed 31 Jul 2026.